The introduction of Retatrutide ZPHC, at a strength of 120mg, is generating considerable interest within the healthcare community. This novel dual GIP and GLP-1 target medication appears to deliver notable improvements in body loss compared to existing therapies. Early patient trials have indicated significant decreases in weight , potentially mark